✦ LIBER ✦

Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy for relapsed or refractory multiple myeloma: a multicenter phase 2 study

✍ Scribed by Takamatsu, Yasushi; Sunami, Kazutaka; Muta, Tsuyoshi; Morimoto, Hiroaki; Miyamoto, Toshihiro; Higuchi, Masakazu; Uozumi, Kimiharu; Hata, Hiroyuki; Tamura, Kazuo

Book ID: 120827236
Publisher: Carden Jennings Publishing
Year: 2013
Tongue: English
Weight: 232 KB
Volume: 98
Category: Article
ISSN: 0925-5710
DOI: 10.1007/s12185-013-1389-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I study of bortezomib in combina

A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma

✍ Yasushi Takamatsu; Kazutaka Sunami; Hiroyuki Hata; Koji Nagafuji; Ilseung Choi; 📂 Article 📅 2010 🏛 Carden Jennings Publishing 🌐 English ⚖ 167 KB

Weekly Bortezomib, Pegylated Liposomal D

Weekly Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone Is a Safe and Effective Therapy for Elderly Patients With Relapsed/Refractory Multiple Myeloma

✍ Alessandro Gozzetti; Alberto Fabbri; Stefania Oliva; Elena Marchini; Monica Bocc 📂 Article 📅 2010 🏛 Elsevier 🌐 English ⚖ 115 KB

Bortezomib, doxorubicin, and dexamethaso

Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety

✍ Sung Sook Lee; Cheolwon Suh; Bong-Seog Kim; Jooseop Chung; Young-Don Joo; Hun-Mo 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 151 KB

Results from AMBER, a randomized phase 2

Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma

✍ Darrell White; Adetola Kassim; Birbal Bhaskar; Jing Yi; Karen Wamstad; Virginia 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 910 KB

Weekly bortezomib in combination with te

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study

✍ Irene M Ghobrial; Edie Weller; Ravi Vij; Nikhil C Munshi; Ranjit Banwait; Meghan 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 210 KB

Updated survival analyses after prolonge

Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma

✍ Sundar Jagannath; Bart Barlogie; James R. Berenson; David S. Siegel; David Irwin 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB